ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
중화 항체 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 이 성장세는 신종 감염병의 증가, 자가면역 질환의 확산, 항체 기반 치료제 파이프라인의 확대, 정밀 의학에 대한 수요 증가, 표적 치료제에 대한 관심 고조 등에 힘입을 것으로 예상됩니다. 예측 기간 동안의 주요 동향으로는 이중 특이성 및 다중 특이성 항체로의 전환, 항체 발견에 인공 지능(AI)의 사용, 항체-약물 복합체의 개발, 식물 기반 항체 생산의 사용 증가, 개인 맞춤형 면역 요법 접근법의 증가 등이 있습니다.
감염성 질환의 유행이 증가함에 따라 향후 몇 년 동안 중화 항체 시장의 성장이 촉진될 것으로 예상됩니다. 감염성 질환은 박테리아, 바이러스, 곰팡이, 기생충 등 유해한 미생물에 의해 발생하며, 한 사람에서 다른 사람으로 직접 또는 간접적으로 전염될 수 있는 질병입니다. 이러한 질병의 발병률이 증가하는 것은 주로 전 세계 여행의 증가로 인해 병원균이 국경을 넘어 빠르게 전파될 수 있기 때문입니다. 중화 항체는 병원균을 특이적으로 표적화하고 차단하여 질병의 진행을 막는 데 중요한 역할을 합니다. 중화 항체는 정확하고 시기적절한 면역 보호를 제공하여 환자의 치료 결과를 개선하는 데 기여합니다. 예를 들어, 2024년 2월 영국 보건 안전청(UK Health Security Agency)은 잉글랜드의 결핵 환자가 2023년 4,850명으로 2022년 4,380명 대비 10.7% 증가했다고 보고했습니다. 이는 전염병의 증가세가 중화 항체 시장 성장을 촉진하고 있음을 보여줍니다.
중화 항체 시장 선도 기업들은 바이러스의 인간 세포 침입을 직접 차단하여 감염성 질환을 더 효과적으로 치료하기 위해 표적 치료제를 포함한 고급 치료법 개발을 우선순위로 두고 있습니다. 표적 치료제는 암이나 바이러스 감염과 같은 질병 유발 세포의 성장과 생존에 필수적인 특정 분자 표적이나 경로를 표적으로 삼아 작용하도록 설계되었습니다. 예를 들어, 2022년 2월, 미국 제약 회사인 Eli Lilly and Company는 COVID-19 치료를 위한 중화 단일 클론 항체 치료제인 Bebtelovimab에 대해 미국 식품의약국(FDA)으로부터 긴급 사용 승인(EUA)을 받았습니다. Bebtelovimab은 중증으로 진행될 위험이 높은 경증에서 중등증 코로나19 환자를 대상으로 하며, 입원 또는 사망 위험이 있는 환자에게 사용됩니다. 이 승인은 새로운 바이러스 변이체의 출현 속에서 치료를 신속히 진행하는 데 기여하여 질병의 중증도를 줄이고 환자 예후를 개선하는 데 도움을 줍니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 중화 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 중화 항체 시장 : 성장률 분석
세계의 중화 항체 시장 실적 : 규모와 성장(2019-2024년)
세계의 중화 항체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 중화 항체 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 중화 항체 시장 항체유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
폴리클로날 항체
세계의 중화 항체 시장 타겟 바이러스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
SARS-CoV-2(COVID-19)
인간 면역결핍 바이러스(HIV)
인플루엔자
에볼라
지카 열
C형 간염
기타 표적 바이러스
세계의 중화 항체 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
최종 사용자에게 직접 판매
리셀러
온라인 소매
기타 유통 채널
세계의 중화 항체 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
치료제
진단
연구개발
세계의 중화 항체 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 및 진료소
연구기관
진단실험실
제약회사
기타 최종 사용자
세계의 중화 항체 시장 : 단일클론항체 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
완전 인간 단일클론항체
인간화 단일클론항체
키메라 단일클론항체
마우스 단일클론항체
세계의 중화 항체 시장 : 폴리클로날 항체 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
동물 유래 폴리클로날 항체
재조합 폴리클로날 항체
인간 폴리클로날 항체 제형
제7장 지역별, 국가별 분석
세계의 중화 항체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 중화 항체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
중화 항체 시장 : 경쟁 구도
중화 항체 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
GlaxoSmithKline plc
Eli Lilly and Company
Regeneron Pharmaceuticals Inc.
GeNext Genomics
Celltrion Healthcare Co. Ltd
BeiGene Ltd
AbCellera Biologics Inc.
BMC Pharmacology and Toxicology
Anthos Therapeutics
Immunome Inc.
Sorrento Therapeutics Inc.
Tonix Pharmaceuticals
Abwiz Bio
AXIM Biotechnologies
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
중화 항체 시장(2029년) : 새로운 기회를 제공하는 국가
중화 항체 시장(2029년) : 새로운 기회를 제공하는 부문
중화 항체 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
A neutralizing antibody is a specific type of antibody that attaches directly to a virus or pathogen, effectively blocking its ability to infect host cells. Its main function is to stop infection by neutralizing the pathogen's harmful effects, thereby halting disease progression.
Neutralizing antibodies primarily come in two forms: monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are lab-engineered molecules tailored to bind to a specific antigen, such as a virus or cancer cell. These antibodies are used to target a range of viruses, including SARS-CoV-2 (COVID-19), HIV, influenza, Ebola, Zika, and hepatitis C, among others. Distribution channels include direct sales to end-users, distributors, online retailers, and other methods. Applications span across therapeutics, diagnostics, and research and development, catering to end-users such as hospitals and clinics, research institutions, diagnostic laboratories, pharmaceutical companies, and others.
The neutralizing antibody market research report is one of a series of new reports from The Business Research Company that provides neutralizing antibody market statistics, including neutralizing antibody industry global market size, regional shares, competitors with a neutralizing antibody market share, detailed neutralizing antibody market segments, market trends and opportunities, and any further data you may need to thrive in the neutralizing antibody industry. This neutralizing antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neutralizing antibody market size has grown rapidly in recent years. It will grow from $230.25 billion in 2024 to $257.81 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. Historical growth has been driven by a rise in biologic drug approvals, increased funding for antibody research, higher prevalence of chronic viral infections, growing awareness of immunotherapy, and expanding healthcare spending.
The neutralizing antibody market size is expected to see rapid growth in the next few years. It will grow to $401.16 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. This expected growth will be fueled by a rise in emerging infectious diseases, increasing autoimmune disorders, expansion of antibody-based therapy pipelines, growing demand for precision medicine, and increased interest in targeted therapies. Key trends over the forecast period include a shift toward bispecific and multispecific antibodies, the use of artificial intelligence (AI) in antibody discovery, the development of antibody-drug conjugates, increased use of plant-based antibody production, and a rise in personalized immunotherapy approaches.
The increasing prevalence of infectious diseases is anticipated to drive the growth of the neutralizing antibody market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread from one person to another either directly or indirectly. The growing incidence of these diseases is largely attributed to the rise in global travel, which enables the rapid transmission of pathogens across borders. Neutralizing antibodies play a crucial role in treating infectious diseases by specifically targeting and blocking pathogens, thereby preventing the progression of illness. They contribute to improved patient outcomes by offering precise and timely immune protection. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, up by 10.7% from 4,380 cases in 2022. This highlights how the rising prevalence of infectious diseases is bolstering the neutralizing antibody market.
Leading companies in the neutralizing antibody market are prioritizing the development of advanced therapies, including targeted treatments, to more effectively combat infectious diseases by directly neutralizing viruses and preventing their entry into human cells. Targeted therapies are designed to act on specific molecular markers or pathways that are essential for the growth and survival of disease-causing cells, such as those involved in cancers or viral infections. For instance, in February 2022, Eli Lilly and Company, a U.S.-based pharmaceutical firm, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Bebtelovimab, a neutralizing monoclonal antibody therapy aimed at treating COVID-19. Bebtelovimab is intended for use in patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death. This approval supports timely treatment efforts amid the emergence of new viral variants, thereby aiding in the reduction of disease severity and enhancement of patient outcomes.
In July 2022, Brii Biosciences Limited, a biotechnology firm based in China, collaborated with China Resources Pharmaceutical Commercial Group Co., Ltd. through its joint venture, TSB Therapeutics (Beijing) Co. Ltd., to support the commercialization of amubarvimab/romlusevimab in China. This partnership is focused on expanding access to the treatment for patients with mild to moderate COVID-19 who are at risk of developing severe illness, and accelerating its availability across the country. China Resources Pharmaceutical Commercial Group Co., Ltd. is engaged in the distribution of neutralizing antibody products within China.
Major players in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, and AXIM Biotechnologies.
North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neutralizing antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the neutralizing antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neutralizing antibody market consists of sales of antibody kits, reagents, and related diagnostic and therapeutic products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in usd, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neutralizing Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neutralizing antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neutralizing antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutralizing antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Antibody Type: Monoclonal Antibodies; Polyclonal Antibodies
2) By Target Virus: SARS-CoV-2 (COVID-19); Human Immunodeficiency Viruses (HIV); Influenza; Ebola; Zika; Hepatitis C; Other Target Viruses
3) By Distribution Channel: Direct Sales To End-Users; Distributors; Online Retail; Other Distribution Channels
4) By Application: Therapeutics; Diagnostics; Research And Development
5) By End User: Hospitals And Clinics; Research Institutes; Diagnostic Laboratories; Pharmaceutical Companies; Other End Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies; Recombinant Polyclonal Antibodies; Human Polyclonal Antibody Preparations
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Neutralizing Antibody Market Characteristics
3. Neutralizing Antibody Market Trends And Strategies
4. Neutralizing Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Neutralizing Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Neutralizing Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neutralizing Antibody Market Growth Rate Analysis
5.4. Global Neutralizing Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neutralizing Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neutralizing Antibody Total Addressable Market (TAM)
6. Neutralizing Antibody Market Segmentation
6.1. Global Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
6.2. Global Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
SARS-CoV-2 (COVID-19)
Human Immunodeficiency Viruses (HIV)
Influenza
Ebola
Zika
Hepatitis C
Other Target Viruses
6.3. Global Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Sales To End-Users
Distributors
Online Retail
Other Distribution Channels
6.4. Global Neutralizing Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutics
Diagnostics
Research And Development
6.5. Global Neutralizing Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Research Institutes
Diagnostic Laboratories
Pharmaceutical Companies
Other End Users
6.6. Global Neutralizing Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fully Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
6.7. Global Neutralizing Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Animal-Derived Polyclonal Antibodies
Recombinant Polyclonal Antibodies
Human Polyclonal Antibody Preparations
7. Neutralizing Antibody Market Regional And Country Analysis
7.1. Global Neutralizing Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neutralizing Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Neutralizing Antibody Market
9.1. China Neutralizing Antibody Market Overview
9.2. China Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Neutralizing Antibody Market
10.1. India Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Neutralizing Antibody Market
11.1. Japan Neutralizing Antibody Market Overview
11.2. Japan Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Neutralizing Antibody Market
12.1. Australia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Neutralizing Antibody Market
13.1. Indonesia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Neutralizing Antibody Market
14.1. South Korea Neutralizing Antibody Market Overview
14.2. South Korea Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Neutralizing Antibody Market
15.1. Western Europe Neutralizing Antibody Market Overview
15.2. Western Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Neutralizing Antibody Market
16.1. UK Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Neutralizing Antibody Market
17.1. Germany Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Neutralizing Antibody Market
18.1. France Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Neutralizing Antibody Market
19.1. Italy Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Neutralizing Antibody Market
20.1. Spain Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Neutralizing Antibody Market
21.1. Eastern Europe Neutralizing Antibody Market Overview
21.2. Eastern Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Neutralizing Antibody Market
22.1. Russia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Neutralizing Antibody Market
23.1. North America Neutralizing Antibody Market Overview
23.2. North America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Neutralizing Antibody Market
24.1. USA Neutralizing Antibody Market Overview
24.2. USA Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
